EyePoint Pharmaceuticals US, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$22.8M
Doctors Paid
2,910
Transactions
9,407
2024 Total
$7.5M
Payment Breakdown by Category
Research$19.1M (83.7%)
Consulting$2.4M (10.4%)
Food & Beverage$374,574 (1.6%)
Travel$142,159 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $19.1M | 536 | 83.7% |
| Consulting Fee | $2.4M | 1,013 | 10.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $808,616 | 199 | 3.5% |
| Food and Beverage | $374,574 | 7,229 | 1.6% |
| Travel and Lodging | $142,159 | 404 | 0.6% |
| Gift | $2,146 | 14 | 0.0% |
| Education | $191.20 | 12 | 0.0% |
Payments by Type
Research
$19.1M
504 transactions
General
$3.7M
8,871 transactions
Ownership
$0
32 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD | $11.4M | 2 | 134 |
| A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) | $2.3M | 1 | 70 |
| A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Diabetic Macular Edema (DME) | $880,259 | 2 | 15 |
| A phase 1, Multicenter, Prospective, Open-Label, Dose escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in subjects with Wet AMD | $861,425 | 0 | 22 |
| A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD | $598,527 | 0 | 34 |
| Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis | $391,793 | 0 | 25 |
| A Phase 3, Multicenter, Prospective, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide (FA) Intravitreal 0.05 mg Insert (Yutiq 0.05 mg) in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye | $390,393 | 1 | 32 |
| Prospective Imaging of the intrAvitreal fluocinoloNe acetonide implant using fluorescein angiography and opTical coHerence tomogRaphy in uveitis patients (PANTHER) | $241,106 | 0 | 2 |
| A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1% | $227,785 | 0 | 3 |
| Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert | $222,293 | 0 | 73 |
| The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial) | $147,375 | 0 | 1 |
| Pending Registration: CALM: Real World Data on Yutiq (fluocinolone acetonide intravitreal implant) 0.18mg | $138,840 | 0 | 1 |
| A study of Yutiq Steriod Insert During Glaucoma Tube Implant Surgery | $130,110 | 0 | 8 |
| A Study of Yutiq Steroid Insert During Glaucoma Tube Implant Surgery | $124,510 | 0 | 15 |
| DEXYCU Retrospective study | $111,070 | 1 | 22 |
| Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-infectious Posterior Segment Uveitis | $104,139 | 0 | 8 |
| A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract | $98,575 | 0 | 9 |
| Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract (EYP-DIP-001) | $91,935 | 0 | 6 |
| Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract | $88,615 | 0 | 6 |
| Pending Registration: Prospective Imaging of the Intravitreal Fluocinolone Acetonide Implant Using Fluorescein Angiography and Optical Coherence Tomography in Uveitis Patients (PANTHER) | $80,000 | 0 | 1 |
| Effect of Intraoperative Dexamethasone on Post-Op Dry Eye | $57,500 | 0 | 1 |
| Effect of Intraoperative Dexamethasone on Post-op Dry Eye | $40,000 | 0 | 1 |
| Injectable Fluocinolone Implant for the Management of Chronic Postsurgical Uveitis and Cystoid Macular Edema | $30,000 | 0 | 1 |
| Retrospective Review of Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated with Vitreoretinal Surgery | $28,245 | 0 | 1 |
| Comparison of intravitreal triamcinolone acetonide, dexamethasone implant and fluocinolone implant on recurrence rates in chronic noninfectious posterior uveitis and the effect of hyperreflective inner retinal line (HIRL) | $28,060 | 1 | 1 |
| A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation | $27,000 | 0 | 1 |
| Prospective Study Comparing Intrvitreal Versus Posterior Chamber Dexycu Administration Following Cataract and Glaucoma Surgery | $25,105 | 0 | 1 |
| Prospective Study Comparing Intravitreal Versus Posterior Chamber Dexycu Administration Following Cataract and Glaucoma Surgery | $25,105 | 0 | 1 |
| A Prospective Study of the Efficacy of Dexycu compared to Standard of Care Treatment for Post-Surgical Pain and Anterior Chamber Inflammation | $25,000 | 0 | 1 |
| Retrospective Review of Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated with Vitreoretinal Surgery: Analysis of Macular Thickness | $24,150 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| David Guyer | Ophthalmology | New York, NY | $228,984 | $0 |
| Dr. Daniel Kiernan, Md, MD | Ophthalmology | Sarasota, FL | $202,473 | $0 |
| Carl Regillo, Md, MD | Ophthalmology | Plymouth Meeting, PA | $176,494 | $0 |
| Charles Wykoff, Md, Phd, MD, PHD | Retina Specialist | Bellaire, TX | $142,626 | $0 |
| Dr. Robert Parnes, Md, MD | Ophthalmology | Hagerstown, MD | $140,932 | $0 |
| Michael Singer, M.d, M.D | Ophthalmology | San Antonio, TX | $139,291 | $0 |
| Dr. Peter Chang, M.d, M.D | Ophthalmology | Waltham, MA | $134,035 | $0 |
| Seenu Hariprasad | Ophthalmology | Chicago, IL | $120,502 | $0 |
| David Boyer, Md, MD | Ophthalmology | Los Angeles, CA | $116,141 | $0 |
| Dr. Sumit Sharma, M.d, M.D | Retina Specialist | Cleveland, OH | $114,426 | $0 |
| Dr. Robert Osher, Md, MD | Ophthalmology | Cincinnati, OH | $88,307 | $0 |
| Cynthia Matossian, Md, MD | Ophthalmology | Pennington, NJ | $82,434 | $0 |
| David Almeida, Md, Mba, Phd, MD, MBA, PHD | Retina Specialist | Erie, PA | $80,092 | $0 |
| Rishi Singh, Md, MD | Ophthalmology | Boston, MA | $73,642 | $0 |
| David Eichenbaum, M.d, M.D | Retina Specialist | St Petersburg, FL | $71,542 | $0 |
| Dr. Dilsher Dhoot, M.d, M.D | Retina Specialist | Santa Barbara, CA | $67,803 | $0 |
| John Hovanesian, M.d, M.D | Ophthalmology | Laguna Hills, CA | $47,581 | $0 |
| Dr. Stephen Anesi, M.d, M.D | Ophthalmology | Waltham, MA | $44,060 | $0 |
| Mark Dacey, Md, MD | Uveitis and Ocular Inflammatory Disease | Denver, CO | $43,753 | $0 |
| Dr. Thomas Albini, Md, MD | Ophthalmology | Miami, FL | $42,037 | $0 |
| Dr. Michael Savetsky, Md, MD | Cornea and External Diseases Specialist | Culver City, CA | $41,853 | $0 |
| Lisa Faia, M.d, M.D | Retina Specialist | Royal Oak, MI | $40,344 | $0 |
| Jason Bacharach, Md, MD | Ophthalmology | Petaluma, CA | $39,933 | $0 |
| Unknown Provider | — | — | $35,134 | $0 |
| Dr. Paul Hahn, Md, MD | Retina Specialist | Nanuet, NY | $32,593 | $0 |
About EyePoint Pharmaceuticals US, Inc.
EyePoint Pharmaceuticals US, Inc. has made $22.8M in payments to 2,910 healthcare providers, recorded across 9,407 transactions in the CMS Open Payments database. In 2024, the company paid $7.5M. The top product by payment volume is EYP-1901 ($16.7M).
Payments were distributed across 50 medical specialties. The top specialty by payment amount is Ophthalmology ($3.0M to 1,980 doctors).
Payment categories include: Food & Beverage ($374,574), Consulting ($2.4M), Research ($19.1M), Travel & Lodging ($142,159).
EyePoint Pharmaceuticals US, Inc. is associated with 3 products in the CMS Open Payments database.